Skip to main content
SpringerLink
Log in

Unkontrollierte komplementäre Medizin verzerrt Studienergebnisse – Pro und Kontra

Oxford-Debatte

Uncontrolled complementary medicine distorts clinical trial results – pros and cons

An Oxford debate

  • Meinung
  • Published:
Forum Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. European Medicines Agency Guideline on the evaluation of anticancer medicinal products in man, Appendix 2: The use of patient-reported outcome (PRO) measures in oncology studies. EMA/CHMP/292464/2014, 1. April 2016

  2. Domnick M, Domnick M, Wiebelitz KR, Beer AM (2017) Evaluation of the effectiveness of a multimodal complementary medicine program for improving the quality of life of cancer patients during adjuvant radiotherapy and/or chemotherapy or outpatient aftercare. Oncology 93(2):83–91

    Article  PubMed  Google Scholar 

  3. Thill M, Liedtke C, Solomayer E‑F, Müller V, Janni W, Schmidt M, AGO Breast Committee (2017) AGO recommendations for the diagnosis and treatment of patients with advanced and metastatic breast cancer: update 2017. Breast Care (Basel) 12:184–191

    Article  Google Scholar 

  4. Shalom-Sharabi I, Lavie O, Samuels N, Keinan-Boker L, Lev E, Ben-Arye E (2017) Can complementary medicine increase adherence to chemotherapy dosing protocol? A controlled study in an integrative oncology setting. J Cancer Res Clin Oncol 143(12):2535–2543

    Article  PubMed  CAS  Google Scholar 

  5. Ernst E, Schmidt K, Steuer-Vogt MK (2003) Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer 107(2):262–267

    Article  PubMed  CAS  Google Scholar 

  6. Horneber MA, Bueschel G, Huber R, Linde K, Rostock M (2008) Mistletoe therapy in oncology. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.cd003297.pub2

    Article  PubMed  Google Scholar 

  7. Melzer J, Iten F, Hostanska K, Saller R (2009) Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review. Forsch Komplementmed 16(4):217–226

    PubMed  Google Scholar 

  8. Jacob SA, Khan TM, Lee LH (2017) The effect of green tea consumption on prostate cancer risk and progression: a systematic review. Nutr Cancer 69(3):353–364

    Article  PubMed  CAS  Google Scholar 

  9. Pittler MH, Ernst E (2007) Clinical effectiveness of garlic (allium sativum). Mol Nutr Food Res 51(11):1382–1385

    Article  PubMed  CAS  Google Scholar 

  10. van Die MD, Bone KM, Williams SG, Pirotta MV (2014) Soy and soy isoflavones in prostate cancer: a systematic review and meta-analysis of randomized controlled trials. BJU Int 113(5b):E119–E130

    Article  PubMed  CAS  Google Scholar 

  11. Yang J, Zhu L, Wu Z, Wang Y (2013) Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.cd005096.pub4

    Article  PubMed  Google Scholar 

  12. Chen X, Deng L, Jiang X, Wu T (2016) Chinese herbal medicine for oesophageal cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.cd004520.pub7

    Article  PubMed Central  PubMed  Google Scholar 

  13. Ziemann J, Ritter CA (2017) Onkologische Medikamente und Phytotherapeutika – Gibt es Wechselwirkungen? J Onkol 10:845–850

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pharmazie – Klinische Pharmazie, Ernst-Moritz-Arndt Universität Greifswald, Friedrich-Ludwig-Jahn-Str. 17, 17489, Greifswald, Deutschland

    Christoph A. Ritter

  2. Klinik Blankenstein, Lehrbereich Naturheilkunde, Ruhr-Universität Bochum, Im Vogelsang 5–11, 45527, Hattingen, Deutschland

    André-Michael Beer

Authors
  1. Christoph A. Ritter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. André-Michael Beer
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

die Arbeitsgemeinschaft Onkologische Pharmazie (OPH)

die Arbeitsgemeinschaft Prävention und Integrative Onkologie (PRiO)

Corresponding author

Correspondence to Christoph A. Ritter.

Ethics declarations

Interessenkonflikt

C.A. Ritter und A.-M. Beer geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ritter, C.A., die Arbeitsgemeinschaft Onkologische Pharmazie (OPH)., Beer, AM. et al. Unkontrollierte komplementäre Medizin verzerrt Studienergebnisse – Pro und Kontra. Forum 33, 162–164 (2018). https://doi.org/10.1007/s12312-018-0433-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12312-018-0433-0

Search

Navigation